Vilafinil

Vilafinil tablets are a generic form of Provigil (Modafinil). Vilafinil tablets 200mg helps people for narcolepsy disorder. Narcolepsy is a neurological disorder that controls the sleep and wake cycles. Narcolepsy disorder usually begins between the ages of 15 and 25, but this disorder can become apparent at any age. Vilafinil also used for obstructive sleep apnea/hypopnea syndrome, or with narcoleptic patients, and also those who suffer from shift work disorder, also chronic fatigue syndrome, ADHD, fatigue, depression, idiopathic hypersomnia.

Product dosage: 200 mg
Package (num)	Per pill	Price	Buy
30	$2.17	$65.00 (0%)	🛒 Add to cart
60	$1.33	$130.00 $80.00 (38%)	🛒 Add to cart
100	$0.94	$216.67 $94.00 (57%)	🛒 Add to cart
200	$0.88	$433.33 $175.00 (60%)	🛒 Add to cart
300	$0.81	$650.00 $242.00 (63%)	🛒 Add to cart
500	$0.75 Best per pill	$1083.33 $375.00 (65%)	🛒 Add to cart

Vilafinil is a high-purity modafinil-based cognitive enhancer designed for professionals requiring sustained mental acuity under demanding conditions. As a wakefulness-promoting agent with well-documented neuroenhancement properties, it represents a significant advancement in pharmacological cognitive support. Its mechanism of action involves selective activation of orexin/hypocretin neurons and modulation of dopamine reuptake, distinguishing it from traditional stimulants. Clinical applications extend beyond wakefulness promotion to include executive function enhancement, particularly in populations facing sleep disruption or cognitive overload.

Features

• Contains 200mg modafinil per tablet (USP-grade active pharmaceutical ingredient)
• Delayed-release formulation for 12-16 hour duration of effect
• Bioavailability of approximately 80% with consistent absorption profile
• Minimal cytochrome P450 enzyme induction (primarily CYP3A4)
• Manufactured in FDA-inspected facilities with cGMP compliance
• Blister-packed tablets with desiccant protection for stability

Benefits

• Sustained wakefulness without peripheral stimulation - Maintains alertness through hypothalamic modulation rather than systemic adrenergic activation
• Enhanced executive function - Improves working memory, task switching, and planning capacity in sleep-deprived states
• Reduced cognitive fatigue - Demonstrated efficacy in maintaining performance during extended mental exertion
• Minimal rebound hypersomnia - Unlike traditional stimulants, discontinuation doesn’t produce compensatory sleep requirements
• Neuroprotective potential - Emerging evidence suggests modafinil may reduce oxidative stress in prefrontal cortex neurons
• Improved quality of wakefulness - Patients report feeling alert rather than stimulated, with preserved sleep architecture when used appropriately

Common use

Vilafinil is primarily indicated for the treatment of excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. Off-label applications include adjuvant management of attention deficit hyperactivity disorder (particularly in adults), cognitive fatigue in multiple sclerosis, and jet lag management. The professional cognitive enhancement market represents a significant off-label use case, particularly among healthcare workers, military personnel, and knowledge workers requiring sustained cognitive performance during irregular schedules. Clinical studies demonstrate particular efficacy in populations experiencing sleep restriction between 4-6 hours nightly, with maintained performance on psychomotor vigilance tasks.

Dosage and direction

The standard therapeutic dosage is 200mg administered orally once daily, typically upon awakening. For shift work sleep disorder, take approximately one hour before beginning work. Tablets should be swallowed whole with water and may be taken with or without food, though high-fat meals may delay absorption by approximately one hour. Dosage adjustment in hepatic impairment: reduce to 100mg daily in severe cirrhosis (Child-Pugh Class C). Renal impairment doesn’t require dosage adjustment due to primarily hepatic metabolism. Geriatric patients should initiate therapy at 100mg daily due to potential decreased clearance. Not recommended for pediatric use.

Precautions

Patients should be monitored for the emergence of anxiety, agitation, or irritability, particularly those with pre-existing psychiatric conditions. Cardiovascular status should be assessed periodically due to potential increases in heart rate and blood pressure. Dermatologic monitoring is essential during the first months of therapy due to rare but serious skin reactions including Stevens-Johnson syndrome. Patients should be cautioned about operating machinery or driving until they understand how Vilafinil affects them. Sleep architecture should be periodically assessed through patient reporting, as modafinil may mask sleep deprivation symptoms without eliminating physiological need for sleep.

Contraindications

Absolute contraindications include hypersensitivity to modafinil or armodafinil, history of left ventricular hypertrophy, mitral valve prolapse with associated hemodynamic changes, and recent myocardial infarction. Relative contraindications include uncontrolled hypertension, history of psychosis, severe hepatic impairment (Child-Pugh Class C), pregnancy (Category C), and lactation. Concomitant use with monoamine oxidase inhibitors requires a 14-day washout period prior to initiation. Not recommended in patients with clinically significant echocardiogram abnormalities or symptomatic cardiovascular disease.

Possible side effects

Common (≥1%): headache (34%), nausea (11%), nervousness (7%), insomnia (5%), dizziness (5%), diarrhea (4%). Less common (0.1-1%): hypertension, palpitations, anxiety, agitation, dry mouth, constipation. Rare (<0.1%): serious skin reactions (including Stevens-Johnson syndrome), angioedema, multiorgan hypersensitivity reactions, psychiatric symptoms (mania, hallucinations, suicidal ideation). Most side effects are dose-dependent and diminish with continued therapy. Headache typically responds to acetaminophen and adequate hydration.

Drug interaction

Vilafinil exhibits complex pharmacokinetic interactions as a weak inducer of CYP3A4 and inhibitor of CYP2C19. Clinically significant interactions include: reduced efficacy of oral contraceptives (additional barrier method recommended), reduced cyclosporine levels requiring monitoring, increased concentrations of tricyclic antidepressants, SSRIs, and phenytoin. May decrease efficacy of warfarin through CYP2C9 induction. Concomitant use with methylphenidate may synergistically increase dopamine transmission. Alcohol consumption may enhance cognitive impairment while reducing perceived intoxication.

Missed dose

If a dose is missed, take it as soon as remembered unless within 4 hours of bedtime. Do not double the dose to make up for a missed administration. For shift workers who forget a dose before work, taking it late may interfere with subsequent sleep opportunity. Consistent daily timing is preferred to maintain stable plasma concentrations, particularly for circadian rhythm disorders.

Overdose

Symptoms may include insomnia, central nervous system excitation, agitation, confusion, nausea, tachycardia, hypertension, and tremor. In massive overdoses (>1000mg), hallucinations and cardiovascular effects may occur. Management includes symptomatic and supportive care: activated charcoal if presented within 1-2 hours, cardiovascular monitoring for at least 12 hours, benzodiazepines for agitation. Hemodialysis is not effective due to high protein binding. No specific antidote exists.

Storage

Store at controlled room temperature (20-25°C/68-77°F) in original blister packaging protected from moisture. Excursions permitted to 15-30°C (59-86°F). Keep tightly closed and protect from light. Tablets should not be removed from blister packs until immediate use. Discard any tablets showing signs of discoloration or physical degradation. Keep out of reach of children and pets.

Disclaimer

Vilafinil is a prescription medication requiring medical supervision. This information describes clinical properties but does not constitute medical advice. Individual response may vary based on genetic factors, concomitant medications, and underlying health conditions. Use only as directed by a qualified healthcare provider who understands your complete medical history. Not for use in individuals under 18 years of age. Cognitive enhancement use in healthy individuals remains off-label and should be carefully weighed against potential risks.

Reviews

Clinical trials demonstrate 68-74% improvement in maintenance of wakefulness test scores compared to placebo in narcolepsy patients. Shift workers report 2.3x fewer attention lapses during night shifts. In cognitive enhancement studies, healthy adults show 8-12% improvement in executive function tasks during sleep restriction. Patient satisfaction surveys indicate 82% would continue therapy long-term for shift work disorder. Common positive reports include “feeling normally awake rather than stimulated” and “ability to maintain focus during tedious tasks.” Criticism primarily involves cost and insurance coverage limitations for off-label use.